Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmasset initiates dosing in Phase I hepatitis trial
Pharmasset has filed an investigational new drug application with the FDA earlier in this quarter of 2009. Michelle Berrey, chief medical officer of Pharmasset, said: “This is a
Pharmasset has filed an investigational new drug application with the FDA earlier in this quarter of 2009. Michelle Berrey, chief medical officer of Pharmasset, said: “This is a
Most recently, Mr Landau has served as vice president of business development and marketing planning and member of the senior management team at Tengion, a regenerative medicine company.
US-based biotechnology company Oxygen Biotherapeutics has added clinical trial sites in Israel for the planned Phase II dose escalation study of Oxycyte in traumatic brain injury. Oxycyte is
As a result of language inserted into a recent appropriations bill which was signed into law, Toxic Release Inventory (TRI) reporting requirements changed on March 11, reverting to
Bristol-Myers Squibb has announced that results from a 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a selective, sodium glucose co-transporter2 inhibitor, produced clinically meaningful reductions across all
In an effort to better serve the batch, custom and specialty chemical industry, SOCMA members voted on March 19th to change the organisation’s name from the Synthetic Organic
Osiris Therapeutics has elected to end enrollment at 210 patients in its Phase III trial evaluating Prochymal for Crohn’s disease. The company believes there is a design flaw
Highlights FDA clearance and launch of second generation instrument platform, eSensor XT-8, with Warfarin sensitivity test CYP4F2 biomarker provides unique position in rapidly developing Warfarin testing market Installed
Galapagos, a drug discovery and development company, has initiated Phase I clinical development of its candidate drug GLPG0259 for rheumatoid arthritis. Galapagos said that the primary endpoints of
Italy-based biopharmaceutical company Gentium has reported encouraging preliminary unaudited top-line results from the Phase II/III European pediatric prevention clinical trial of defibrotide. The Phase II/III European pediatric prevention